MAP Publication

ISPOR 2016 – Vienna: Predicting Orphan Designation and Marketing Authorisation Based on a Review of the European Medicines Agency Orphan Disease Register

2016 |

Current projections of European and worldwide expenditure on orphan drugs are contrasting. The aim of this research was to identify trends in the orphan drug designations (ODDs) and marketing authorisations (MAs) awarded by the European Medicines Agency (EMA) following the introduction of the EU Regulation on orphan medicinal products in 2000.

Download


All Publications